Tzu-Fei Wang

Tzu-Fei Wang

MD, MPH

Scientist, Inflammation and Chronic Disease

Ottawa Hospital Research Institute

Associate professor, Division of Hematology

Department of Medicine

Bio

Tzu-Fei Wang, MD, MPH is a hematologist and an associate professor in the Division of Hematology, Department of Medicine at the University of Ottawa and the Ottawa Hospital and a Scientist at the Ottawa Hospital Research Institute. Her main areas of clinical and research interest include clinical research for the optimal prevention and treatment strategies for patients with cancer-associated thrombosis, drug-drug interactions with anticoagulants, and obesity-related thromboembolism. She holds a Tier 2 Clinical Research Chair in Cancer and Thromboembolism from the University of Ottawa. She has received research funding from the International Society on Thrombosis and Haemostasis (ISTH), the Canadian Institutes of Health Research (CIHR), The Ottawa Hospital Academic Medical Organization (TOHAMO), and the International Network of VENous Thromboembolism Clinical Research Networks (INVENT). She is currently the Chair of the ISTH (International Society on Thrombosis and Haemostasis) Live Courses Subcommittee of the Education Committee. She was a co-chair of the Hemostasis and Malignancy Subcommittee of the International Society on Thrombosis and Haemostasis from 2018 to 2022.

Research Goals and Interests

Cancer-associated Venous thromboembolism, including prevention and management strategies
Obesity related thromboembolism and anticoagulant strategies
Drug-drug interactions with anticoagulants


News


Publications

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL

2026-02-10 Go to publication

Association Between Bariatric Surgery and the Long‐Term Risk for Venous Thromboembolism: A Population‐Based Matched Cohort Study

2026-01-26 Go to publication

Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation

2026-01-01 Go to publication

A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study

2026-01-01 Go to publication

Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers

2025-12-12 Go to publication

2024-2025 - CIHR - The impact of language on care and outcomes in patients with prostate or breast cancer ($100,000)

2024-2025 - INVENT-VTE - A pilot randomized controlled trial assessing the strategies for Anticoagulation in patients with thrombocytopenia and cancer-associated Thrombosis (START pilot trial) ($20,000)

2024-2027 - TOHAMO- A prospective management cohort study of catheter-related upper extremity deep vein thrombosis in patients with cancer: the STREAM-Line Study ($100,000)

2023-2024 - CIHR- EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort ($164,476)

2022-2026 - TOHAMO - START pilot randomized controlled trial (STrategies for Anticoagulation in patients with thRombocytopenia and cancer-associated Thrombosis) ($181,100)

2021- 2023- CIHR - Reducing bleeding with DOACs in breast cancer patients: The STOP-Bleed Cancer Study ($110,000)

2018-2020 - ISTH - An international registry of the safety and efficacy in cancer patients with concurrent use of direct oral anticoagulants and targeted cancer therapies (TacDOAC registry) ($25,900.82)


Related Research at The Ottawa Hospital